| Term 
 
        | What are the 6 main classes of antihypertensive drugs? |  | Definition 
 
        | 
 1.  Diuretics 2.  Sympatholytics (Antiadrenergics) 
Alpha 1 BlockersCentrally acting Alpha 2 AgonistsBeta Adrenergic BlockersCombination Alpha & Beta Blockers 3.  ACE Inhibitors (Angiotensin-Converting Enzyme Inhibitors) 4.  CCBs (Calcium Channel Blockers 5.  ARBs (Angiotensin II Receptor Blockers) 6.  Direct-Acting Vasodilators |  | 
        |  | 
        
        | Term 
 
        | What are the Sympatholytics (Antiadrenergics)? |  | Definition 
 
        | 
   Sympatholytics (Antiadrenergics) 
Alpha 1 BlockersCentrally acting Alpha 2 AgonistsBeta Adrenergic BlockersCombination Alpha & Beta Blockers |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | prototype Anti-adrenergic or adrenergic antagonists 
   Selective alpha 1 blockade causes dilation of arterioles & veins (alpha1 adrenergic blocker) 
  HTN, BPH      Orthostatic hypotension, tachycardia 
   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Anti-adrenergic or adrenergic antagonists Indirect acting alpha 2 agonists prototype Acts in CNS.  Selective activation of alpha 2 receptors, which decreases sympathetic outflow to blood vessels and heart; results in bradycardia, decr cardiac output (CO), decr BP      HTN   Severe cancer pain 
    Rare rebound HTN with drug withdrawal Drowsiness Dry mouth  Withdraw drug slowly over 2-4 days generally free of serious side effects effects kidneys more than lopressor |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | most important Anti-adrenergic or adrenergic antagonists beta-adrengergic blockers nonselective prototype          
blocks beta 1 and beta 2 receptors; results in decreased HR, net effect is decr. CO; highly lipid soluble     
   Also suppresses rennin secretion 
  HTN, angina, dysrhythmias, MI, migraine, “stage fright” 
  
Bradycardia (hold for HR <60 and SBP <100 Heart block Heart failure (Contraindicated with preexisting HF) Bronchoconstriction (caution with asthma & COPD) Decr. Glycogenolysis (danger with diabetes) (impedes early recognition of insulin-induced hypoglycemia) Crosses CNS 
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Anti-adrenergic or adrenergic antagonists cardioselective prototype  Selective blockage of beta 1 receptors of heart; results in decreases in HR, renin secretion    Preferred for pts with asthma or diabetes; HTN, angina, heart failure, MI 
   
Bradycardia, decreased cardiac output, AV block, rebound tachycardia (withdraw drug slowly), heart failureHold for SBP < 100 and HR < 60   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Anti-adrenergic or adrenergic antagonists combination alpha and beta blockers prototype    Combination alpha & beta blocker; dilates blood vessels    HTN, MI   Orthostatic hypotension, tachycardia Rare rebound HTN with drug withdrawal Drowsiness Dry mouth  Withdraw drug slowly over 2-4 days      
Bradycardia (hold for HR <60 and SBP <100 Heart block Heart failure (Contraindicated with preexisting HF) Bronchoconstriction (caution with asthma & COPD) Decr. Glycogenolysis (danger with diabetes) (impedes early recognition of insulin-induced hypoglycemia) Crosses CNS Bradycardia, decreased cardiac output, AV block, rebound tachycardia (withdraw drug slowly), heart failure 
 
     |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Block Na+ and Cl- reabsorption (and thus H2O); results in Na+, Cl-, H2O excretion    
4 major categories: ·       High ceiling loop diuretics (furosemide) ·       Thiazide diuretics (HCTZ) ·       Osmotic diuretics (mannitol)K+ sparing diuretics (spironolactone |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Drugs Acting on the RAAS angiotensin-converting enzyme inhibitors (ACEI) prototype  ACE Inhibitor; decr levels of angiotensin II and incr levels of bradykinin; causes arteriole vasodilation, decr blood volume        
HTN, heart failure, MI, prevent or reverse pathophysiologic effects on heart & kidney ; prevent MI, stroke, death in high risk CV pts      Cough (5-10% incidence); if cough, stop med Angioedema  1st dose can cause signif hypotension Hyperkalemia (hold for K+ > 5.0) Contraindicated: pregnancy (fetal injury); pts with renal artery stenosis Interactions: med + diuretic = hypotension Med + other HTN meds = additive effects Med + lithium = toxic lithium levelsNSAIDS or ASA may decrease antihypertensive effects of med         |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Drugs Acting on the RAAS angiotensinII receptor blockade (ARB) prototype    HTN, MI, diab. Nephropathy, MI, CVA prevention  
         
Angioedema—NEVER give again if this develops (med may increase bradykinin synthesis)Contraindications: pregnancy (fetal harm), renal artery stenosis           |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Drugs Acting on the RAAS selective aldosterone antagonists prototype  Selective blockade of aldosterone receptors; causes K+ retention, Na+ and H2O excretion, decreased BP and decr blood volume    HTN, heart failure 
 Hyperkalemia (hold for K+ > 5.0) Caution with ACEI or ARB or decr. Renal function Contraindications: K+ supplement, salt sub, K+ sparing diuretics Interactions: Increased med levels if given with erythromycin, verapamil, fluconazole; 5X if given with ketoconazole; med + lithium = incr lithium lvls   
   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CCBs non-dihydropyridines prototype  Blocks Ca++ channels in heart and blood vessels; dilates arterioles to decr BP and incr coronary perfusion; AV node blockade decr HR and AV node conduction (MOST IMPORTANT EFFECT); decr myocardial contractility    Angina, HTN, atrial flutter, atrial fib, PSVT      
Dizzy, HA, ankle & foot edema, eczematous rash in elderly Cautions: Heart block, bradycardia, heart failureInteractions: Increases plasma Digoxin levels 60%   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CCB dihydropridines prototype    Vasodilation causes decr BP; increased coronary perfusion; activates baroreceptor reflex to incr HR   (No suppressant effects on HR, AV conduction or contractility)    HTN, angina of effort, vasospastic angina, investigational for migraines & preterm labor      Reflex tachycardia; dizzy, flushing, rash, peripheral edema, HA, gingival hyperplasia Interactions: Beta blockers prevent reflex tachycardia   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
 Direct-Acting Vasodilators prototype  Selective dilation of arterioles to decrease SVR (afterload), decr BP; also increases HR and increases myocardial contractility by reflex mechanisms    HTN, hypertensive crisis, angina, short term use in HF, pheochromocytoma, pulm artery hypertension, PVD    
Headache, dizzy, postural hypotension, reflex tachycardia, SLE, increased blood volume Interactions: Beta blockers protect against reflex tachycardia, yet can worsen heart failure and increase blood volume Med + other HTN meds = additive effects |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | anticoagulant prototype  rapid acting (in minutes); helps antithrombin III inactivate thrombin, factor Xa & others to suppress fibrin formation    Since fibrin forms framework of thrombi in veins, esp useful for VTE prophylaxis; pulmonary embolus, evolving CVA or MI, massive DVT, open heart pts, renal dialysis, DIC    
Bleeding is complication in 10% of pts Treat overdose with PROTAMINE SULFATE. Hemorrhage, thrombocytopenia (check platelets 2-3 x/week first 3 weeks of heparin therapy), hypersensitivity, local irritation & hematoma, vasospastic reactions; long term use can cause osteoporosis. Contraindications:  thrombocytopenia, uncontrollable bleeding, dur & after eye, brain, spinal cord surgeries, LPs, regional anesthesia Highly cautious with pts with high likelihood of bleeding (hemophilia, peptic ulcer, severe HTN)Interactions:  any drug that suppresses platelet formation (ASA, NSAID) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |  
 low molecular weight heparin prototype  Shorter molecular chain than Heparin; inactivates factor Xa; less effect in inactivation of thrombin    VTE prophylaxis, DVT with or without pulm embolus; prevention of ischemic complications in unstable angina, non Q wave MI, STEMI    
Advantages—as effective as unfractionated Heparin, can be given on fixed dose schedule, don’t need aPTT monitoring, can be used at home, less likely to cause thrombocytopeniaCan cause bleeding, but less than Heparin |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | lowmolecular weight heparin  Antagonist of Vit K at synthesis sites     Long term prophylaxis of thrombosis, prevention of pulm embolus, pts with prosthetic heart valves, atrial fib, risk of recurrent TIA & MI     
Hemorrhage  Don’t use during pregnancy or lactation Skin necrosis, alopecia, dermatitis, fever, GI disturbances, red-orange urine Contraindications:  thrombocytopenia, high risk for bleeding, HTN, Vit K deficiency, liver disease, alcoholism.  Antidote  is VITAMIN K. |  | 
        |  | 
        
        | Term 
 
        | 
 Aspirin (ASA) + dipyridamole (Aggrenox) |  | Definition 
 
        | antiplatelet prototype  ASA irreversibly inhibits cyclooxygenase and prostacyclin causing decreased platelet activity; dipyridamole also suppresses platelet    MI prophylaxis, prevention of reinfarction, stroke prevention, TIA, chronic stable angina, after coronary stent, AMI, after valve replacement    
GI bleeding, hemorrhagic strokeCombination of meds more effective than single use in prevention of cardiac incidents. |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | adenosine diphosphate receptor antagonists prototype  
Irreversible blockade of ADP receptors on platelet surfaces (for life of the platelet)    MI and CVA prevention, after stents    
Similar to ASA.  Less incidence of intracranial bleeding than ASA, possible TTPCaution with PPIs—may decrease antiplatelet effect |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | initiates vasoconstriction in smooth muscle |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | prevents CNS initiation of SNS activity |  | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | prevent constriction in vascular smooth muscle (HTN with BPH) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | bronchioconstriction, vasoconstriction, inhibit glycogenolysis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | decrease CO, supress renin secretion in kidney, calcium channel blocker, decrease HTN, decrease a fib |  | 
        |  | 
        
        | Term 
 
        | 
 Spasm   Involuntary contractions                    treatment?                               |  | Definition 
 
        | 
 Analgesics                                                                        Anti-inflammatory agents                                                            NSAIDs Valium (diazepam) Soma (carisoprodol) |  | 
        |  | 
        
        | Term 
 
        | 
 .                         Spasticity                              CNS disorders   treatment? |  | Definition 
 
        | 
 Baclofen (lioresal): muscle relaxant centrally-acting prototype |  | 
        |  | 
        
        | Term 
 
        | muscle relaxant: centrally acting prototypes? |  | Definition 
 
        | 
 Baclofen (lioresal) and carisoprodol (soma) |  | 
        |  | 
        
        | Term 
 
        | 
 Management of Osteoporosis: |  | Definition 
 
        | 
 1.      Bisphosphonates—prototype: Fosamax (alendronate)           2.     Miacalcin (calicitonin-salmon) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | cell wall weakening agent prototypes: Pen G, Nafcillin, Amplicillin   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | cell wall weakening agent four generation prototypes. each stronger than last gen 4: cefepime distributes well in most tissues excretion by renals caution with allergies bleeding - vit K interference use with AAPC- c. diff. |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | cell wall weakening agent prototype: vancocin potentially very toxic save for worst of infections: gram pos. staph a. use as alternative to penicillin allergy patients use with AAPC/c.diff. use with mrsa distributes well in all tissues except CSF excreted by renals - monitor renal labs SE: ototoxicity renal toxicity thrombophlebitis VRE  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | cell wall weakening agent prototype: imipenem |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | bacteriostatic inhibitor prototypes: tetracycline (short acting), doxycline (long acting) broad spectrum gram pos. and gram neg. static only seldom used as first line of defense short, intermittent, long acting decreased absorption: food, Calcium, iron, magnesium, antacids widley distributed - not in CSF excreted in renal and hepatic systems SE: nvd, cramping, burning - give with food, stains teeth so dont give to preg. womn or children,exacerbation of preexisting renal diseases used for aapc/c.diff. |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
bacteriostatic inhibitor prototype: erythromycin |  | 
        |  | 
        
        | Term 
 | Definition 
 
        |   
bacteriostatic inhibitor prototypes: linezolid   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | bacterialcidal inhibitor prototype: gentamicin narrow spectrum bactericidal commonly used as combo drug distribution to renal and ear cells monitor renal labs closely unmetabolized by hepatic system can cause tinnitus can cause dizziness, headache, ATN proteinuria, increases BUN and Cr., ototoxicity, vertigo 
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | inhibitors of cell wall synthesis broad spectrum prototype |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 
inhibitors of cell wall synthesis extended spectrum prototype |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | broad spectrum, widely used effective w/gram neg. and some gram pos. not effective w/ c.diff. absorbed quickly but incompletely interacts with calcium, iron, antacids used for: URI, UTI, GI tract concentration in urine stool bile SE: GI upset, oral candida, tendon rupture, interacts with coumadin |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | selective: COX 2 inhibitors: celecoxib (celebrex) Vioxx (Rofecoxib) was withdrawn voluntarily from the market, due to an increased risk of myocardial infarction and stroke |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | uses: essential hypertension, reversal of toxicity from alpha 1 agonists, benign prostatic hyperplasia adverse rxn of alpha 1 blockade: orthostatic hypotension, reflex tachycardia, nasal congestion, inhibition of ejaculation adverse rxn of alpha 2 bloackade: potentiation of the reflex tachycardia that can occur in response to blockade of alpha 1 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | uses: angina, HTN, cardia dysrhythmias, MI, HF, hyperthyroidism, migrain, stage freight, glaucoma adverse rxn to beta 1 blockade: bradycardia, reduced CO, HF, AV heart block adverse rxn to beta 2 blockade: bronchoconstriction, inhibition of glycogenolysis |  | 
        |  |